A5111855012- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Breast Lesions and Carcinomas
- Estrogen and related hormone effects
- Peroxisome Proliferator-Activated Receptors
- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Brain Metastases and Treatment
- Peptidase Inhibition and Analysis
- Cancer Cells and Metastasis
- Cancer Risks and Factors
- Cancer-related molecular mechanisms research
- RNA Research and Splicing
- NF-κB Signaling Pathways
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Breast Implant and Reconstruction
- Cancer, Lipids, and Metabolism
- Adipose Tissue and Metabolism
- Metabolism, Diabetes, and Cancer
- Nutritional Studies and Diet
- Chemotherapy-related skin toxicity
- Signaling Pathways in Disease
Fowler Kennedy Sport Medicine Clinic
2025
Western University
2025
Dalhousie University
2004-2020
National Cancer Center
2011-2020
Asan Medical Center
2011-2019
Seoul National University Hospital
2007-2019
University of Ulsan
2012-2019
Yonsei University
2011-2019
Samsung Medical Center
2012-2019
Sungkyunkwan University
2013-2019
In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy pertuzumab, trastuzumab, and docetaxel, as compared placebo, docetaxel. Overall pertuzumab in an interim analysis without the median being reached. We report final prespecified overall results a follow-up of 50 months.We randomly assigned who had not received previous chemotherapy or anti-HER2 their...
Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 CDK6), which promote progression from the G1 phase to S cell cycle. We assessed efficacy palbociclib (an inhibitor CDK4 CDK6) fulvestrant in advanced cancer.This 3 study involved 521 patients with hormone-receptor-positive, human epidermal growth factor receptor 2-negative that had relapsed or progressed during prior endocrine therapy. randomly assigned a 2:1 ratio receive placebo...
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We report the results of a prespecified analysis overall survival. randomly assigned HER2-negative cancer who had progression or relapse during previous endocrine therapy to receive palbociclib plus placebo fulvestrant. analyzed...
We have isolated the mouse gene encoding adipocyte P2, aP2, differentiation-dependent protein homologous to myelin P2. The aP2 is present in a single copy and or few copies species from human Drosophila. entire spans 4 kilobases consists of four exons 25, 57, 34, 16 amino acids; overall exon structure similar liver fatty acid binding protein. A plasmid vector was constructed containing with flanking sequences, modified by linker insertion. When this stably introduced into 3T3-F442A cells, it...
Abstract Background. Palbociclib enhances endocrine therapy and improves clinical outcomes in hormone receptor (HR)-positive/human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (MBC). Because this is a new target, it clinically important to understand palbociclib’s safety profile effectively manage toxicity optimize benefit. Materials Methods. Patients with endocrine-resistant, HR-positive/HER2-negative MBC (n = 521) were randomly assigned 2:1 receive fulvestrant (500 mg...
Abstract Purpose: HER2-positive breast cancer is heterogeneous. Some tumors express mutations, like activating PIK3CA mutations or reduced PTEN expression, that negatively correlate with response to HER2-targeted therapies. In this exploratory analysis, we investigated whether the efficacy of trastuzumab emtansine (T-DM1), an antibody–drug conjugate comprised cytotoxic agent DM1 linked antibody trastuzumab, was correlated expression specific biomarkers in phase III EMILIA study. Experimental...
Micropapillary carcinoma or a micropapillary component has been reported in the ovary, breast, and urinary bladder is generally thought to have prognostic significance. However, little written on differentiation lung carcinoma. We studied 35 cases of primary adenocarcinoma with seen at M.D. Anderson Cancer Center. The these tumors ranged from focal prominent was both metastatic sites. This not associated any particular histologic subtype adenocarcinoma. Of 15 available material, 14 (93%)...
The CYP3A and CYP2D6 enzymes play a major role in converting tamoxifen to its active metabolites. is highly inducible enzyme, regulated mainly by pregnane X receptor (PXR). This study assessed the association between genetic polymorphisms of PXR, pharmacokinetics (PK) clinical outcomes patients with breast cancer.Plasma concentrations metabolites were measured. Common alleles PXR identified 202 treated 20 mg daily for more than 8 weeks. Twelve an additional nine metastatic cancer receiving...
Abstract Introduction Brain metastases (BM) occur in up to one third of patients with metastatic breast cancer (MBC), whose incidences and prognoses by subtypes BM have not been well delineated. Methods Retrospective survival analyses were performed 126 from 805 MBC treated at the National Cancer Center between August 2001 April 2006, according clinical characteristics, subtypes, receipt trastuzumab. Estrogen receptor (ER), progesterone (PR), human epidermal growth receptor-2 (HER2) statuses...
We sought to determine whether the combination of ixabepilone plus capecitabine improved overall survival (OS) compared with alone in patients metastatic breast cancer (MBC) previously treated anthracyclines and taxanes.A total 1,221 MBC anthracycline taxanes were randomly assigned (40 mg/m(2) intravenously on day 1) (2,000 orally days 1 through 14) or (2,500 same schedule) given every 21 days. The trial was powered detect a 20% reduction hazard ratio (HR) for death.There no significant...
Prognostic predictors for node-negative breast carcinoma have not been clearly established. Immunostaining with Ki-67 antibody was performed on frozen sections of histologically proved carcinomas from 42 patients to examine its prognostic value and association other clinicopathologic biochemical parameters, i.e., patient age tumor size, histologic type, nuclear grade, mitotic rate, presence vascular or lymphatic invasion, DNA ploidy, percentage cells in S-phase, estrogen content, c-erbB-2...
Adipocyte differentiation is accompanied by the transcriptional activation of many new genes, including gene encoding adipocyte P2 (aP2), an intracellular lipid-binding protein. Using specific deletions and point mutations, we have shown that at least two distinct sequence elements in aP2 promoter contribute to expression chloramphenicol acetyltransferase chimeric constructions transfected into adipose cells. An AP-I site -120, earlier bind Jun- Fos-like proteins, serves as a positive...
In the PALOMA-3 study, palbociclib plus fulvestrant demonstrated improved progression-free survival compared with placebo in hormone receptor-positive, HER2- endocrine-resistant metastatic breast cancer (MBC). This analysis patient-reported outcomes (PROs) between two treatment groups.Patients were randomized 2 : 1 to receive 125 mg/day orally for 3 weeks followed by week off (n = 347) (500 mg i.m. per standard of care) or 174). PROs assessed on day cycles 1-4 and every other subsequent...
Abstract Background The efficacy and safety of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, combined with fulvestrant goserelin was assessed in premenopausal women advanced breast cancer (ABC) who had progressed on prior endocrine therapy (ET). Patients Methods One hundred eight endocrine-refractory ≥18 years hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) ABC were among 521 randomized 2:1 (347:174) to (500 mg) ± either palbociclib (125...
Aims The prognosis of metaplastic breast cancer (MBC) is reportedly worse than that triple-negative invasive ductal carcinoma (TN-IDC), but the determinants poor are not yet known. Methods Patients from two Korean centres were included in this study (67 MBC and 520 TN-IDC). Characteristics disease groups, including clinical parameters, histological features, chemoresponsiveness, recurrence survival estimates, evaluated. Results presented with larger tumours, more frequent distant metastasis...